Published in BJOG on February 01, 2000
Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet (2015) 7.50
Differential methylation profile of ovarian cancer in tissues and plasma. J Mol Diagn (2008) 1.02
A new computer-aided diagnostic tool for non-invasive characterisation of malignant ovarian masses: results of a multicentre validation study. Eur Radiol (2010) 0.82
Ovarian tumor characterization and classification using ultrasound-a new online paradigm. J Digit Imaging (2013) 0.80
GyneScan: an improved online paradigm for screening of ovarian cancer via tissue characterization. Technol Cancer Res Treat (2013) 0.75
Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA (1998) 6.34
Screening for ovarian cancer: a pilot randomised controlled trial. Lancet (1999) 5.81
An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med (1996) 3.86
Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ (1996) 2.19
Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol (2000) 2.04
The clinical course of osteoporosis in anorexia nervosa. A longitudinal study of cortical bone mass. JAMA (1991) 1.93
p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet (1998) 1.79
Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst (1993) 1.71
A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet (2001) 1.70
Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med (2001) 1.69
PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer (2001) 1.63
Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol (2007) 1.61
Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst (1993) 1.60
Hormonal profiles after the menopause. Br Med J (1976) 1.58
Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev (2001) 1.55
Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med (2000) 1.55
Screening for ovarian cancer. Ann Intern Med (1994) 1.53
Evidence of infection with simian type D retrovirus in persons occupationally exposed to nonhuman primates. J Virol (2001) 1.42
Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med (1997) 1.40
The distribution of CA 125 in the reproductive tract of pregnant and non-pregnant women. Br J Obstet Gynaecol (1988) 1.40
Seborrhoeic Verrucae and Multiple Basal-celled Epitheliomata. Proc R Soc Med (1932) 1.37
Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol (1995) 1.27
Endocrine changes and symptomatology after oophorectomy in premenopausal women. Br J Obstet Gynaecol (1977) 1.26
Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. BJOG (2011) 1.23
Evaluating a designated family planning clinic within a genitourinary medicine clinic. Genitourin Med (1995) 1.22
Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol (2002) 1.21
Molecular quantification and mapping of lymph-node micrometastases in cervical cancer. Lancet (2001) 1.21
Feasibility of screening for ovarian cancer using symptoms as selection criteria. BJOG (2007) 1.15
Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation. Br J Cancer (1999) 1.13
The role of CA 125 in screening for ovarian cancer. Int J Biol Markers (1999) 1.12
A comparison of national cancer registry and direct follow-up in the ascertainment of ovarian cancer. Br J Cancer (1999) 1.10
Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. Br J Cancer (2009) 1.08
Ascites and a raised serum Ca 125--confusing combination. J R Soc Med (2001) 1.08
A model for co-expression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancer. Br J Cancer (2002) 1.08
Changing blood use in the AIDS era: the case of elective hip surgery. Transfusion (1994) 1.07
Lichen Nitidus. Proc R Soc Med (1931) 1.06
Celebrities and screening: a measurable impact on high-grade cervical neoplasia diagnosis from the 'Jade Goody effect' in the UK. Br J Cancer (2013) 1.05
Recent developments in ovarian cancer screening. Curr Opin Obstet Gynecol (2000) 1.02
The role of magnetic resonance imaging and ultrasound in patients with adnexal masses. Clin Radiol (2005) 1.02
Three-dimensional in vitro cell biology models of ovarian and endometrial cancer. Cell Prolif (2009) 1.02
Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res (1989) 1.02
Role of MR imaging in the selection of patients with early cervical carcinoma for fertility-preserving surgery: initial experience. Radiology (1999) 1.00
Radical trachelectomy: a way to preserve fertility in the treatment of early cervical cancer. Br J Obstet Gynaecol (1998) 1.00
The use of the LARS artificial ligament to augment a short or undersized ACL hamstrings tendon graft. Knee (2010) 1.00
Ovarian cancer screening in the general population. Curr Opin Obstet Gynecol (2001) 0.99
Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res (2000) 0.97
Differential diagnosis of adnexal masses: risk of malignancy index, ultrasonography, magnetic resonance imaging, and radioimmunoscintigraphy. Int J Gynecol Cancer (2007) 0.97
Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3. Obstet Gynecol (1992) 0.96
Postmenopausal women undergoing transvaginal ultrasound screening prefer not to have chaperones. BJOG (2006) 0.96
Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas. Cancer Res (2000) 0.95
Screening for ovarian cancer. Ann Acad Med Singapore (1998) 0.93
Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecol Oncol (1984) 0.93
Detection of tumour lymphovascular space invasion using dual cytokeratin and CD31 immunohistochemistry. J Clin Pathol (2003) 0.90
Can MRI rule out bladder and rectal invasion in cervical cancer to help select patients for limited EUA? Gynecol Oncol (2005) 0.90
The effects of Arcanobacterium pyogenes on endometrial function in vitro, and on uterine and ovarian function in vivo. Theriogenology (2007) 0.90
A new treatment for endometrial cancer with gonadotrophin releasing-hormone analogue. Br J Obstet Gynaecol (1991) 0.89
Survival analysis in familial ovarian cancer, a case control study. Eur J Obstet Gynecol Reprod Biol (2001) 0.89
The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men. Br J Urol (1998) 0.89
Long-term follow-up of gonadotrophin-releasing hormone analog treatment for recurrent endometrial cancer. Gynecol Oncol (1996) 0.88
MR imaging of uterine sarcomas. AJR Am J Roentgenol (2001) 0.88
Screening for simian type-D retrovirus infection in macaques, using nested polymerase chain reaction. Lab Anim Sci (1997) 0.88
Ovarian cancer screening in the general population: current status. Int J Gynecol Cancer (2001) 0.88
Radical trachelectomy in early stage carcinoma of the cervix: outcome as judged by recurrence and fertility rates. BJOG (2001) 0.87
Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. J Clin Pathol (1999) 0.85
Differences between hereditary and sporadic ovarian cancer. Eur J Obstet Gynecol Reprod Biol (1999) 0.84
Serum oestrogen receptor alpha and beta bioactivity are independently associated with breast cancer: a proof of principle study. Br J Cancer (2009) 0.84
Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women. Cancer (1999) 0.83
Comparative genomic hybridization of microdissected familial ovarian carcinoma: two deleted regions on chromosome 15q not previously identified in sporadic ovarian carcinoma. Lab Invest (2001) 0.83
Length of stay in the intensive care unit. Effects of practice guidelines and feedback. JAMA (1990) 0.82
Somatic mitochondrial DNA mutations in primary and metastatic ovarian cancer. Gynecol Oncol (2006) 0.81
Prevalence of consanguineous marriages in South Sinai, Egypt. J Biosoc Sci (2012) 0.81
Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3. Br J Obstet Gynaecol (1993) 0.81
Clinical course of stage IV epithelial ovarian cancer. J Clin Oncol (1999) 0.81
Social and behavioural factors associated with HIV seroconversion in homosexual men attending a central London STD clinic: a feasibility study. AIDS Care (2000) 0.81
The human nasal mucosa in the menstrual cycle. A histochemical and electron microscopic study. J Laryngol Otol (1981) 0.81
Model for the molecular genetic diagnosis of endometrial cancer using K-ras mutation analysis. J Natl Cancer Inst (1998) 0.81
Early diagnosis of ovarian cancer. Br J Hosp Med (1990) 0.80
Redefining a critical region of LOH on 4p16.3 in bladder cancer. Genes Chromosomes Cancer (2000) 0.80
Adjuvant postoperative radiation therapy for colonic carcinoma. Ann Surg (1987) 0.79
Grading of serous ovarian carcinoma: further evidence of a lack of agreement between conventional grading systems. Histopathology (2007) 0.79
A study of pressure distributions measured during balanced and unbalanced sitting. J Bone Joint Surg Am (1982) 0.79
Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer. Mol Pathol (2002) 0.79